The Claim
Plasma phosphorylated tau (p-tau217) exhibits a consistent breakpoint at age 72.6 in a mass spectrometry subsample, with alignment to p-tau181, indicating its reliability as a biomarker for emerging tau pathology in late midlife.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people aged around 72.6, levels of a specific form of tau protein in blood called p-tau217 show a distinct change that matches changes in another tau marker, p-tau181, suggesting this protein can reliably detect early tau-related brain changes in late midlife.
See the scientific wording
Plasma phosphorylated tau (p-tau217) shows a consistent breakpoint at age 72.6 in a mass spectrometry subsample, aligning with p-tau181 and reinforcing its potential as a reliable biomarker for emerging tau pathology in late midlife.
As people age past 70, brain cells begin to accumulate a modified form of tau protein, which spills into the blood at a consistent rate starting around age 72.6, and this same pattern appears in another similar protein, signaling the start of brain changes linked to Alzheimer’s.
What the research says
1 studyScientists found that a specific protein in the blood called p-tau217 starts rising sharply around age 72, just like another similar protein called p-tau181. This suggests p-tau217 could be a good early warning sign for brain changes linked to Alzheimer’s.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.